Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

Expanded access No longer available Sundar Jagannath Bristol-Myers Squibb · collab

To provide elotuzumab treatment for single-patient use.

Evaluation	Drug	Modality	Dose	Route
Subject	Elotuzumab	Monoclonal antibody	10 mg/kg	Intravenous